NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder

NCT07474974

RecruitingNA

Sponsor: Polytechnic Institute of Porto

Conditions: Depression - Major Depressive Disorder, Treatment Resistant Depression

Interventions: Repetitive transcranial magnetic stimulation (rTMS)

Countries: Portugal

This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in treatment-resistant depression (TRD). We also aim to assess the impact of TMS treatment on RGCs and ipRGCs in TRD patients, investigating associations with clinical improvements and cognitive status. A clinical trial involving 44 patients with treatment-resistant depression (TRD) will be conducted. All participants will receive rTMS targeting the dorsolateral prefrontal cortex (DLPFC). Data will be collected pre- and post-intervention, as well as at a 2-month follow-up, using multiple outcome measures, including the post-illumination pupil response (PIPR). The project seeks to confirm the effectiveness of TMS and the potential of RGCs/ipRGCs as predictors of treatment response, thereby facilitating the development of personalized treatment strategies for TRD patients undergoing rTMS therapy.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of MDD, confirmed via the structured clinical interview;
* TRD type;
* Age between 18-65 years;
* Visual acuity of 20/32 or better.

Exclusion Criteria:

* Prior rTMS treatment;
* Contraindications for TMS;
* Psychiatric disorders other than MDD;
* Systemic diseases affecting the eyes (e.g., diabetes mellitus);
* Ocular conditions;
* Head injuries causing loss of consciousness;
* Current or past alcohol/substance dependence within 6 months;
* Neurodegenerative diseases;
* Major neurological illnesses;
* Use of medications affecting iris mechanics or the autonomic nervous system.

Locations (1)

Porto, Porto District, Portugal